TISSUE PLASMINOGEN ACTIVATOR LEVEL LINKED TO RISK OF STROKE
This article was originally published in The Gray Sheet
Executive Summary
TISSUE PLASMINOGEN ACTIVATOR LEVEL LINKED TO RISK OF STROKE, especially thromboembolic stroke, according to results of a study appearing in the April 16 issue of The Lancet. Led by Paul Ridker, MD, Brigham and Women's Hospital and Harvard Medical School, Boston, the researchers concluded that "in this prospective study of apparently healthy men, a high t-PA antigen was associated with an increased risk of future stroke."
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.